Penicillamine was used in the treatment of rheumatoid arthritis first by Jaffe in 1964 and . In 1973 the multicentre controlled trial (Multicentre Trial Group 1973) confirmed the effectiveness of D-penicillamine in the treatment of active rheumatoid arthritis (RA). Subsequently the effects of D-penicillamine were shown to be similar to those of gold .
In a previous communication, the in vitro penicillamine-treated serum of the patients with RA showed a significant fall in titers of rheumatoid factor and also depolymerization of the macroglobulin containing the rheumatoid factor as evidenced by the ultracentrifugal patterns. These findings suggested the possibility that the immune response is suppressed by penicillamine (Kosaka 1969 Taisho  Pharmaceutical Co., was administered orally to 13 adult patients (2 males, 11 females) with classical or definite RA in a daily dose of 300 mg for the first 4 weeks and then in a daily dose of 600 mg during the period of treatment.
All the patients received 30 mg of pyridoxine hydro. chloride per day in conjunction with D-Penicillamine.
Most of the patients also received non-steroid anti-inflammatory drues such as indomethacin. The determination of T-and B-lymphocytes from the peripheral blood of the patients was carried out before treatment and at 4 weeks, 12 weeks and 24 weeks of treatment.
At each determination, the levels of serum immunoglobulins (IgG and IgM) were determined and RA tests were carried out. The rheumatoid activity index with an aim for the evaluation of the clinical effects was calculated at 4-weeks intervals until the 24th week and then at intervals of 1 month.
Separation of lymphocytes
Peripheral blood lymphocytes were isolated from the fresh heparinized blood from healthy donors and patients, respectively. The lymphocytes for experiments were prepared using a method of Ficoll-Isopaque centrifugation of Jondal et al. (1972) . Each blood sample was laid over an equal volume of a mixture of 24 parts of 9% Ficoll and 10 parts of Isopaque in 10-ml test tubes and was centrifuged for 30 min at room temperature.
The lymphocyte-rich fraction thus obtained from the Ficoll-Isopaque-plasma interface was aspirated and washed three times with phosphate-buffered saline (PBS) of pH 7.2.
T-lymphocyte marker
The T-lymphocytes were identified by the criterion of spontaneous rosette formation with sheep red blood cells (SRBC) according to a modification of the method of Jondal et al. (1972) . The lymphocytes (1.2 x 106) in 0.3 ml of medium TC 199 were mixed with an equal volume of a 0.5% suspension of washed SRBC in PBS containing 10% of fetal calf serum absorbed previously with SRBC. The resulting mixture was centrifuged at 1,000 rpm for 5 min and then kept at room temperature for 1 hr. The pellet of the cells was resuspended carefully. Then an aliquot of the resuspended cell layer was withdrawn and the percentage of the rosette-forming lymphocytes (with a minimum of 5 attached SRBC) was counted microscopically.
B-lymphocyte marker
The B-lymphocytes were identified by the presence of surface immunoglobulins according to a modification of the method of Papamichail et al . (1971) .
Approximately 1-2 x 106 lymphocytes were suspended in 0 .05 ml of a 1:10 dilution of fluorescein-conjugated rabbit anti-human IgG (y-chain) or anti-human IgM ( ,u-chain) Immunoglobulins and rheumatoid factor
The serum concentration of IgG and IgM respectively was measured with a Partigen plate-kit (Behring-Werke) by the technique of single radial immunodiffusion.
In the detection of rheumatoid factor, the commercially available RA-test kit (Hyland) was used . In all the patients the rheumatoid factor was positive before treatment.
Measurements of percent reduction of B-lymphocytes or serum immunoglobulins, and percent increment of T-lymphocytes
The percent reduction and percent increment were calculated by the following formula: Percent reduction or increment=(B/A-1)
x 100
A: percent before treatment B: percent after treatment
Rheumatoid activity index (%)
The rheumatoid activity index (Lansbury 1958 ) was calculated on the basis of the following findings: 1) duration of morning stiffness, 2) grip strength, 3) number of clinically active, painful joints, 4) ESR (1 hr value by Westergren method).
RESULTS
The percentage of T-lymphocytes was found to be increased in almost all the cases. There was a gradual increase of the percentage of T-lymphocytes with time of treatment. The mean of percent increment was 17% at 4 weeks, 23% at 12 weeks and 37% at 24 weeks of treatment in comparison with the percentage of Tlymphocytes before treatment (Fig. 1) lymphocytes was more remarkable and accelerated than that of the surface IgGbearing lymphocytes (Fig. 2) . The concentration of serum IgG was found to be decreased in almost all the cases. The mean of the percent reduction was 15% at 4 weeks , 27% at 12 weeks and 18% at 24 weeks of treatment. Also the concentration of serum IgM was found to be decreased in almost all of the cases. The mean of the percent reduction was 17% at 4 weeks, 26% at 12 weeks and 42% at 24 weeks of treatment . Thus, the rate of decrease of IgM was more remarkable than that of IaG (Fig . 3) . The rheumatoid activity index on an average became smaller with time in almost all of the cases. However, when the dosis of D-penicillamine was decreased because of the improvement of clinical symptoms after 12 months of treatment, there was a transient elevation of rheumatoid activity index (Fig. 4) . Fig. 4 .
Effect of D-penicillamine therapy on rheumatoid activity index in patients with RA.
DISCUSSION
The rationale for the application of D-penicillamine in the treatment of RA is the observation that this drug acted as a dissociative agent on disulfide bonds of the rheumatoid factor (Jaffe 1962; Kosaka 1969 Kosaka , 1970 .
Then the effect in vitro of penicillamine on cultured human lymphocytes which were stimulated with phytohaemagglutinin was investigated by Roath and Wills (1974) . The drug in this system proved to be an effective inhibitor of lymphocyte transformation and, presumably, of immunoglobulin synthesis. They also demonstrated that the effect of D-penicillamine seemed to be dose-related and that D-penicillanne had no cytotoxicity. Thus the effect on the function of lymphocytes was interpreted as a clear reflection of the immunosuppresive effects of Dpenicillamine. Similar results were reported by Schumacher et al. (1975) . In their experiments the metabolism of lymphocytes stimulated by different agents was dose-dependently inhibited by D-penicillamine. The influence of D-penicillamine on the metabolism of lymphocyte, once the stimulatory effect had been established, decreased with time. When preincubated with D-penicillamine, the inhibitory effect on metabolism of lymphocytes was dose-dependent. The inhibitory effect observed in the mixed lymphocyte cultures was much less weaker after preincubation of the stimulator cells than of the responder cells. The inhibitory effect of D-Denicillaminee on the growth of Hela-cells was also dose-dependent.
Despite these experimental evidences, found no evidence of any in vivo change which could be correlated with the effect of Dpenicillamine on T-lymphocytes.
They found no suppression of the responsiveness to intradermal injection of tuberculin or keyhole limpet hemocyanin in their patients who were treated with D-penicillamine. On the other hand, it was claimed that in the treatment of RA the effect of penicillamine was due to the suppressive effect on lymphocytes (Brandt and Svensson 1975) . The number of lymphocyte was significantly smaller in patients treated with penicillamine with a reduction of T-lymphocytes and other lymphocytes. It is to be emphasized that the present study dealt with the effect in vivo of D -penicillamine on the function of T-and B-lymphocytes.
In When treated with penicillamine, the degree of agglutination in RA tests became weaker. The weaker agglutination seemed to be related to the reduction of serum IgM and with the dissociation of rheumatoid factors in vitro in the previous report of the present author (Kosaka 1969 
